
    
      In this Phase II, open-label study patients (16 per treatment group) are randomized to
      receive 1592U89 in combination with one of five protease inhibitors: indinavir, saquinavir,
      ritonavir, nelfinavir, or 141W94 for up to 48 weeks.
    
  